What a Sentinel Node Biopsy Tells You and What the MSLT Trials Changed

A sentinel lymph node biopsy is a staging test, not a treatment. It tells you whether the first lymph node draining a melanoma already contains tumor cells, which is one of the strongest predictors of how the disease is likely to behave. The MSLT-II trial, published in the New England Journal of Medicine in 2017, tested whether removing the rest of the nodes after a positive sentinel biopsy helps patients live longer. It did not. Three-year melanoma-specific survival was 86 percent whether the remaining nodes were removed immediately or simply watched, which cleanly separates the biopsy's prognostic value from any therapeutic benefit of wider surgery.

What a sentinel node biopsy actually measures

When a melanoma spreads, it tends to travel first through lymphatic channels to a specific "sentinel" node, the one that drains that patch of skin. The node is located by injecting a tracer near the primary tumor, following it to the node, and removing that node for the pathologist to examine. If it is clear, the odds that cancer has reached the regional nodes are low. If tumor cells are present, the stage rises and the estimated prognosis shifts.

The important word is measures. The procedure reads biology that is already present. It does not change where the cancer has traveled; it reports it. That distinction sits at the center of every argument about what to do next.

The staging value came first

The foundational trial, MSLT-I, reported its final results in the New England Journal of Medicine in 2014. Across roughly 2,000 patients with primary cutaneous melanoma, sentinel-node biopsy did not improve melanoma-specific survival in the population as a whole, but it delivered accurate staging and better regional disease control, and node status stood out as the most powerful predictor of outcome. That is why the biopsy became standard for intermediate-thickness tumors. It sorts patients into meaningfully different risk groups and informs decisions about surveillance and adjuvant drug therapy.

MSLT-I left one question open. When the sentinel node was positive, standard practice was to go back and remove all the remaining nodes in that basin, an operation called completion lymph node dissection. Did that second surgery add survival, or only morbidity?

What MSLT-II tested

MSLT-II, led by Mark Faries and colleagues, enrolled patients whose sentinel node contained melanoma and randomly assigned them either to immediate completion dissection or to observation with regular nodal ultrasound. Nearly 1,940 patients were randomized. The primary endpoint was melanoma-specific survival.

The result was clear and, for many surgeons, uncomfortable. Three-year melanoma-specific survival was 86 percent in both arms, with no statistical difference. Removing the additional nodes did not help patients live longer.

What the extra surgery did and did not do

The dissection was not without effect; it did specific, measurable things. It improved regional disease control, meaning fewer cancers returned in that lymph node basin. Disease-free survival was modestly higher, 68 percent versus 63 percent at three years, a gap driven mostly by those regional recurrences rather than by distant spread. And it produced information. About 11.5 percent of dissection patients had additional positive nodes beyond the sentinel, and that finding carried real prognostic weight, associated with a substantially higher risk of recurrence.

Against those benefits sat a concrete harm. Lymphedema, the chronic and sometimes disabling swelling that follows node removal, occurred in about 24 percent of the dissection group compared with roughly 6 percent under observation. The trade was more information and better local control on one side, and four times the rate of a lasting complication on the other, with no gain in survival.

Prognosis versus treatment

This is the conceptual heart of the story. A test can be extremely informative and still not be a therapy. The sentinel node biopsy earns its place because knowing node status changes the estimate of risk and, increasingly, the decision about whether to offer adjuvant immunotherapy or targeted therapy. The completion dissection can also be informative, since non-sentinel-node status refines the prognosis further. But information about the future is a different thing from changing it. MSLT-II showed that responding to a positive sentinel node with more surgery buys cleaner local control and sharper staging, not longer life.

The reason the survival curves converge is straightforward. Careful ultrasound surveillance catches most basin recurrences early enough to operate then, and any melanoma destined to spread beyond the nodes has, in most cases, already seeded microscopically by the time the sentinel node turns positive. Removing the neighboring nodes does not undo that.

How the guidance changed

The American Society of Clinical Oncology and the Society of Surgical Oncology folded these findings into their joint guideline update, published in the Journal of Clinical Oncology in 2018. Completion dissection is no longer the automatic answer to a positive sentinel node. Careful observation with nodal ultrasound is now an accepted option for many patients, and the choice is individualized around tumor burden in the sentinel node, the feasibility of close follow-up, and how a patient weighs staging certainty against the risk of lymphedema.

None of this is medical advice, and staging decisions belong in a conversation with a treating oncology and surgical team who can see the whole picture. The value of reading the evidence directly is that it reframes the question. After a positive sentinel biopsy, the honest question is no longer "how much should we cut," but "what will this information change, and is the cost of getting it worth what it buys."